A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors

Summary

This phase I trial studies the side effects and best dose of SOR-C13 in treating patients with solid tumors that have spread to other places in the body (advanced) and does not respond to treatment. Drugs used in chemotherapy, such as SOR-C13, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Conditions

• Advanced Malignant Solid Neoplasm
• Refractory Malignant Solid Neoplasm
• Refractory Ovarian Carcinoma
• Refractory Pancreatic Carcinoma
• Stage II Pancreatic Cancer AJCC v8
• Stage IIA Pancreatic Cancer AJCC v8
• Stage IIB Pancreatic Cancer AJCC v8
• Stage III Ovarian Cancer AJCC v8
• Stage III Pancreatic Cancer AJCC v8
• Stage III Prostate Cancer AJCC v8
• Stage IIIA Ovarian Cancer AJCC v8
• Stage IIIA Prostate Cancer AJCC v8
• Stage IIIB Ovarian Cancer AJCC v8
• Stage IIIB Prostate Cancer AJCC v8
• Stage IIIC Ovarian Cancer AJCC v8
• Stage IIIC Prostate Cancer AJCC v8
• Stage IV Ovarian Cancer AJCC v8
• Stage IV Pancreatic Cancer AJCC v8
• Stage IV Prostate Cancer AJCC v8
• Stage IVA Ovarian Cancer AJCC v8
• Stage IVA Prostate Cancer AJCC v8
• Stage IVB Ovarian Cancer AJCC v8
• Stage IVB Prostate Cancer AJCC v8

Interventions

DRUG

TRPV6 Calcium Channel Inhibitor SOR-C13

Given IV

Sponsors & Collaborators

• National Cancer Institute (NCI)

  collaborator NIH

• M.D. Anderson Cancer Center

  lead OTHER

Principal Investigators

• Siqing Fu · M.D. Anderson Cancer Center

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2019-07-29

Primary Completion

2023-06-20

Completion

2023-06-20

FDA Drug

Yes

Countries

• United States

Study Locations